David A. Siegel Vaxart, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $551,760 - $1.3 Million	-919,600 Reduced 83.64%	179,900 $131,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $679,825 - $1.2 Million	-957,500 Reduced 46.55%	1,099,500 $835,000
Q4 2022 Feb 14, 2023	BUY	$0.75 - $2.24 $1.53 Million - $4.57 Million	2,041,500 Added 13170.97%	2,057,000 $1.97 Million
Q3 2022 Nov 14, 2022	BUY	$2.09 - $4.5 $32,394 - $69,750	15,500 New	15,500 $34,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $101,790 - $199,056	-37,700 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.29 - $6.64 $23,595 - $36,520	-5,500 Reduced 12.73%	37,700 $190,000
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $249,263 - $343,872	43,200 New	43,200 $271,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.